Article

Topical gentamicin and ethacrynic acid: effects on cochlear function.

Hearing Research Laboratories, Division of Otolaryngology--Head and Neck Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
The Laryngoscope (Impact Factor: 1.98). 08/1998; 108(7):1087-9. DOI: 10.1097/00005537-199807000-00024
Source: PubMed

ABSTRACT To determine whether concurrent intravenous administration of the loop diuretic ethacrynic acid potentiates the toxicity of the aminoglycoside antibiotic gentamicin applied topically on the round window.
The authors studied the effects on cochlear sensitivity of co-administered intracardiac ethacrynic acid (40 mg/kg) and high-dose topical gentamicin solution (100%) applied to the round window. Comparisons were made with animals receiving ethacrynic acid plus systemic gentamicin (100 mg/kg); topical gentamicin alone; systemic gentamicin alone; and intravenous ethacrynic acid alone.
Experiments were carried out on pigmented guinea pigs weighing 400 to 500 g. Changes in cochlear function were characterized by monitoring shifts in compound action potential (CAP) thresholds by use of chronic indwelling electrodes implanted at the round window, vertex, and contralateral mastoid.
After 20 days animals receiving ethacrynic acid in combination with topical gentamicin to the round window failed to demonstrate a significant deterioration in cochlear sensitivity, whereas all animals receiving systemic gentamicin plus ethacrynic acid experienced profound increases in CAP thresholds.
This study supports the contention that ethacrynic acid potentiates aminoglycoside ototoxicity by facilitating the entry of the antibiotics from the systemic circulation into the endolymph. In addition, this study answers important clinical concerns regarding the safety of the use of topical aminoglycoside agents in combination with loop diuretics.

0 Bookmarks
 · 
60 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A series of five silver coordination polymers [(AgL1)·(AgCF3COO)5·(H2O)3] (1), [(AgL1)2·(AgCF3COO)11·(H2O)6] (2), [(AgL2)·(AgCF3COO)3·(H2O)] (3), [(AgL3)·(AgCF3COO)4·(CH3CN)2] (4), and [(AgL3)·(AgCF3COO)7·(CH3CN)2·(H2O)2] (5) have been constructed from three flexible anionic ligands HL1, HL2, and HL3 (HL1 = 1-chloro-2-(prop-2-ynyloxy)benzene, HL2 = 1-chloro-3-(prop-2-ynyloxy)benzene, HL3 = 1-chloro-4-(prop-2-ynyloxy)benzene). In these compounds, the invariable appearance of the μ4- and μ5-ligation modes of the ethynide moiety affirms the general utility of the flexible silver-ethynide supramolecular synthon o-, m-, p-Cl−C6H5OCH2CC⊃Agn (n = 4, 5) in coordination network assembly. Among them, Ag⋯Cl interaction plays a vital role in assembling the supramolecular structures in complexes 1−3.
    Journal of Organometallic Chemistry 08/2011; 696(s 15–16):2820–2828. · 2.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Drug ototoxicity represents one of the main preventable causes of deafness. Ototoxicity is a trait shared by aminoglycoside and macrolide antibiotics, antimalarial medications, loop diuretics, platinum-based chemotherapeutic agents, some NSAIDs and most recently described, acetaminophen when abused with narcotic medication. These medications are prescribed despite their side effects, which includes inner ear toxicity, because they are life-saving drugs or there is a lack of better treatment. AREAS COVERED: This review will discuss in vitro and in vivo models of ototoxicity highlighting recently published ototoxicity research. The reader will learn the strengths and limitations of different ototoxicity models and what molecular insights have been gained from their application. A better understanding of the cellular mechanisms of these ototoxins will help in the discovery of ways to prevent and treat hearing loss associated with ototoxic medications. EXPERT OPINION: There are benefits to both in vitro and in vivo models of ototoxicity. Research of a particular medication and its ototoxic mechanisms should draw from several models, enabling a better answer to the clinical question of prevention and treatment of inner ear drug toxicity.
    Expert Opinion on Drug Metabolism &amp Toxicology 12/2011; 7(12):1521-34. · 2.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Concurrent administration of a high dose of gentamicin (GM; 125mg/kg IM) and ethacrynic acid (EA; 40mg/kg IV) results in rapid destruction of virtually all cochlear hair cells; however, the cell death signaling pathways underlying this rapid form of hair-cell degeneration are unclear. To elucidate the mechanisms underlying GM/EA-mediated cell death, several key cell death markers were assessed in the chinchilla cochlea during the early stages of degeneration. In the middle and basal turns of the cochlea, massive hair-cell loss including destruction of the stereocilia and cuticular plate occurred 12h after GM/EA treatment. Condensation and fragmentation of outer hair-cell nuclei, morphological features of apoptosis, were first observed 5-6h post-treatment in the basal turn of the cochlea. Metabolic function, reflected by succinate dehydrogenase histochemistry and mitochondrial staining, decreased significantly in the basal turn 4h following GM/EA treatment; these early changes were accompanied by the release of cytochrome c from the mitochondria into the cytosol and intense expression of initiator caspase-9 and effector caspase-3. GM/EA failed to induce expression of extrinsic initiator caspase-8. These results suggest that the rapid loss of hair cells following GM/EA treatment involves cell death pathways mediated by mitochondrial dysfunction leading to the release of cytochrome c, activation of initiator caspase-9 and effector caspase-3.
    Hearing research 09/2009; 259(1-2):16-23. · 2.18 Impact Factor